Home LiteratureArticle Details
PMID: 20008648 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Mild cognitive impairment: ten years later.

Archives of neurology ·Vol. 66 ·No. 12 ·2009-12-00 ·Pages 1447-55

Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack CR

Abstract

In the past 10 years, there has been a virtual explosion in the literature concerning the construct of mild cognitive impairment. The interest in this topic demonstrates the increasing emphasis on the identification of the earliest features of cognitive disorders such as Alzheimer disease and other dementias. Mild cognitive impairment represents the earliest clinical features of these conditions and, hence, has become a focus of clinical, epidemiologic, neuroimaging, biomarker, neuropathological, disease mechanism, and clinical trials research. This review summarizes the progress that has been made while also recognizing the challenges that remain.

MeSH Terms
Alzheimer Disease/diagnosis,metabolism,psychology Clinical Trials as Topic/trends Cognition Disorders/diagnosis,metabolism,psychology Humans
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Petersen Ronald C
Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. [email protected]
Roberts Rosebud O
Knopman David S
Boeve Bradley F
Geda Yonas E
Ivnik Robert J
Smith Glenn E
Jack Clifford R
References (57)
57 references, click to expand
  1. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions.
    Neurology. 2005 Mar 8;64(5):834-41 PMID: 15753419
  2. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment.
    Lancet Neurol. 2003 Jan;2(1):15-21 PMID: 12849297
  3. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    JAMA. 2009 Jul 22;302(4):385-93 PMID: 19622817
  4. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.
    JAMA. 1995 Apr 26;273(16):1274-8 PMID: 7646655
  5. Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging.
    Neurology. 2001 Nov 13;57(9):1655-62 PMID: 11706107
  6. Relationships between biomarkers in aging and dementia.
    Neurology. 2009 Oct 13;73(15):1193-9 PMID: 19822868
  7. Safety and efficacy of galantamine in subjects with mild cognitive impairment.
    Neurology. 2008 May 27;70(22):2024-35 PMID: 18322263
  8. Current concepts in mild cognitive impairment.
    Arch Neurol. 2001 Dec;58(12):1985-92 PMID: 11735772
  9. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
    Neuropsychopharmacology. 2005 Jun;30(6):1204-15 PMID: 15742005
  10. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease.
    Neurobiol Aging. 2007 Sep;28(9):1330-9 PMID: 16860440
  11. Vitamin E and donepezil for the treatment of mild cognitive impairment.
    N Engl J Med. 2005 Jun 9;352(23):2379-88 PMID: 15829527
  12. Mild cognitive impairment should be considered for DSM-V.
    J Geriatr Psychiatry Neurol. 2006 Sep;19(3):147-54 PMID: 16880356
  13. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment.
    Arch Neurol. 2003 May;60(5):729-36 PMID: 12756137
  14. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Lancet Neurol. 2006 Mar;5(3):228-34 PMID: 16488378
  15. Classification criteria for mild cognitive impairment: a population-based validation study.
    Neurology. 2001 Jan 9;56(1):37-42 PMID: 11148233
  16. Mild cognitive impairment.
    Lancet. 2006 Apr 15;367(9518):1262-70 PMID: 16631882
  17. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.
    Ann Neurol. 2000 Apr;47(4):430-9 PMID: 10762153
  18. Amyloid imaging in mild cognitive impairment subtypes.
    Ann Neurol. 2009 May;65(5):557-68 PMID: 19475670
  19. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts.
    Arch Neurol. 2009 Sep;66(9):1151-7 PMID: 19752306
  20. Conversion to dementia from mild cognitive disorder: the Cache County Study.
    Neurology. 2006 Jul 25;67(2):229-34 PMID: 16864813
  21. Mild cognitive impairment as a diagnostic entity.
    J Intern Med. 2004 Sep;256(3):183-94 PMID: 15324362
  22. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD.
    Neurology. 2003 Jan 28;60(2):253-60 PMID: 12552040
  23. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Brain. 2008 Mar;131(Pt 3):665-80 PMID: 18263627
  24. Mild cognitive impairment: clinical characterization and outcome.
    Arch Neurol. 1999 Mar;56(3):303-8 PMID: 10190820
  25. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
    Ann Neurol. 2009 Apr;65(4):403-13 PMID: 19296504
  26. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.
    Neurology. 2010 Jan 19;74(3):201-9 PMID: 20042704
  27. Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria.
    Arch Neurol. 2006 Jan;63(1):15-6 PMID: 16401731
  28. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics.
    Neuroepidemiology. 2008;30(1):58-69 PMID: 18259084
  29. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
    Science. 1993 Aug 13;261(5123):921-3 PMID: 8346443
  30. Vascular risk factors, incidence of MCI, and rates of progression to dementia.
    Neurology. 2004 Nov 23;63(10):1882-91 PMID: 15557506
  31. Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease.
    Am J Geriatr Psychiatry. 2008 Jul;16(7):603-11 PMID: 18591580
  32. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.
    Nat Rev Drug Discov. 2007 Apr;6(4):295-303 PMID: 17347655
  33. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1.
    Arch Neurol. 2003 Oct;60(10):1385-9 PMID: 14568808
  34. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Lancet Neurol. 2007 Jun;6(6):501-12 PMID: 17509485
  35. Prevalence of mild cognitive impairment: a population-based study in elderly subjects.
    Acta Neurol Scand. 2002 Sep;106(3):148-54 PMID: 12174174
  36. Frequency and course of mild cognitive impairment in a multiethnic community.
    Ann Neurol. 2008 Apr;63(4):494-506 PMID: 18300306
  37. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.
    Arch Neurol. 2006 May;63(5):674-81 PMID: 16682537
  38. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Neurology. 2001 May 8;56(9):1133-42 PMID: 11342677
  39. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Neurology. 2009 May 5;72(18):1555-61 PMID: 19176895
  40. CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia.
    Neurology. 2007 May 29;68(22):1909-16 PMID: 17536047
  41. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment.
    Neurocase. 2005 Feb;11(1):3-7 PMID: 15804918
  42. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
    Brain. 2009 May;132(Pt 5):1355-65 PMID: 19339253
  43. Mild cognitive impairment, amnestic type: an epidemiologic study.
    Neurology. 2004 Jul 13;63(1):115-21 PMID: 15249620
  44. Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population.
    J Am Geriatr Soc. 2008 Jan;56(1):51-8 PMID: 18028343
  45. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.
    Neurology. 1999 Apr 22;52(7):1397-403 PMID: 10227624
  46. Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment.
    J Neurol. 1999 Jun;246(6):477-85 PMID: 10431775
  47. An epidemiologic study of mild cognitive impairment in Kolkata, India.
    Neurology. 2007 Jun 5;68(23):2019-26 PMID: 17548552
  48. Prevalence of cognitive impairment without dementia in the United States.
    Ann Intern Med. 2008 Mar 18;148(6):427-34 PMID: 18347351
  49. Neuropathologic features of amnestic mild cognitive impairment.
    Arch Neurol. 2006 May;63(5):665-72 PMID: 16682536
  50. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia.
    Neurology. 2007 Jan 23;68(4):288-91 PMID: 17242334
  51. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.
    J Intern Med. 2004 Sep;256(3):240-6 PMID: 15324367
  52. The Clinical Dementia Rating (CDR): current version and scoring rules.
    Neurology. 1993 Nov;43(11):2412-4 PMID: 8232972
  53. Neuropathologic substrate of mild cognitive impairment.
    Arch Neurol. 2006 Jan;63(1):38-46 PMID: 16401735
  54. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study.
    Brain. 2010 Feb;133(Pt 2):540-56 PMID: 19889717
  55. Correlation between rates of brain atrophy and cognitive decline in AD.
    Neurology. 1999 May 12;52(8):1687-9 PMID: 10331700
  56. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort.
    Neurology. 2002 Nov 26;59(10):1594-9 PMID: 12451203
  57. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
    Ann Neurol. 2004 Mar;55(3):306-19 PMID: 14991808
Article Info
Journal
Archives of neurology
Abbr.
Arch Neurol
ISSN
1538-3687
DOI
10.1001/archneurol.2009.266
Email
[email protected]
Published
2009-12-00
Pages
1447-55
Language
English
Region
United States
NLM ID
0372436
PMCID
PMC3081688
Subset
IM
Grants
NIA NIH HHS · R01 AG11378 · United States
NIA NIH HHS · P50 AG016574 · United States
NIA NIH HHS · R01 AG011378 · United States
NIA NIH HHS · P50 AG016574-11 · United States
NIA NIH HHS · U01 AG06786 · United States
NIMH NIH HHS · K01 MH68351 · United States
NIA NIH HHS · R01 AG011378-17 · United States
NIA NIH HHS · U01 AG006786 · United States
NIA NIH HHS · P50 AG16574 · United States
NIMH NIH HHS · K01 MH068351 · United States
NIA NIH HHS · U01 AG024904 · United States
NIA NIH HHS · U19 AG010483 · United States
NIA NIH HHS · U01 AG006786-24 · United States
NIMH NIH HHS · K01 MH068351-07 · United States
External Links
PubMed source DOI: 10.1001/archneurol.2009.266 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2